199 related articles for article (PubMed ID: 15475447)
1. Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer.
Ishikawa S; Takenaka K; Yanagihara K; Miyahara R; Kawano Y; Otake Y; Hasegawa S; Wada H; Tanaka F
Clin Cancer Res; 2004 Oct; 10(19):6579-85. PubMed ID: 15475447
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody.
Tanaka F; Otake Y; Yanagihara K; Kawano Y; Miyahara R; Li M; Yamada T; Hanaoka N; Inui K; Wada H
Clin Cancer Res; 2001 Nov; 7(11):3410-5. PubMed ID: 11705856
[TBL] [Abstract][Full Text] [Related]
3. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small-cell lung cancer.
Suzuki M; Iizasa T; Fujisawa T; Baba M; Yamaguchi Y; Kimura H; Suzuki H
Invasion Metastasis; 1998-1999; 18(3):134-41. PubMed ID: 10474026
[TBL] [Abstract][Full Text] [Related]
4. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
Yuan A; Yu CJ; Shun CT; Luh KT; Kuo SH; Lee YC; Yang PC
Int J Cancer; 2005 Jul; 115(4):545-55. PubMed ID: 15704107
[TBL] [Abstract][Full Text] [Related]
5. Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer.
Mino N; Takenaka K; Sonobe M; Miyahara R; Yanagihara K; Otake Y; Wada H; Tanaka F
J Surg Oncol; 2007 Mar; 95(3):250-7. PubMed ID: 17323339
[TBL] [Abstract][Full Text] [Related]
6. Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer.
Takenaka K; Ishikawa S; Kawano Y; Yanagihara K; Miyahara R; Otake Y; Morioka Y; Takahashi C; Noda M; Wada H; Tanaka F
Eur J Cancer; 2004 Jul; 40(10):1617-23. PubMed ID: 15196549
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer.
Leinonen T; Pirinen R; Böhm J; Johansson R; Kosma VM
Histol Histopathol; 2008 Jun; 23(6):693-700. PubMed ID: 18366007
[TBL] [Abstract][Full Text] [Related]
8. Tumor angiogenesis in predicting the survival of patients with stage I lung cancer.
Medetoglu B; Gunluoglu MZ; Demir A; Melek H; Buyukpinarbasili N; Fener N; Dincer SI
J Thorac Cardiovasc Surg; 2010 Nov; 140(5):996-1000. PubMed ID: 20708755
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer.
Cox G; Jones JL; O'Byrne KJ
Clin Cancer Res; 2000 Jun; 6(6):2349-55. PubMed ID: 10873086
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer.
Shao W; Wang W; Xiong XG; Cao C; Yan TD; Chen G; Chen H; Yin W; Liu J; Gu Y; Mo M; He J
J Surg Oncol; 2011 Dec; 104(7):841-6. PubMed ID: 21721010
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer.
O'Byrne KJ; Koukourakis MI; Giatromanolaki A; Cox G; Turley H; Steward WP; Gatter K; Harris AL
Br J Cancer; 2000 Apr; 82(8):1427-32. PubMed ID: 10780522
[TBL] [Abstract][Full Text] [Related]
12. Prognostic effect of matrix metalloproteinase-9 in patients with resected Non small cell lung cancer.
Lee CY; Shim HS; Lee S; Lee JG; Kim DJ; Chung KY
J Cardiothorac Surg; 2015 Mar; 10():44. PubMed ID: 25888323
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary emphysema and tumor microenvironment in primary lung cancer.
Murakami J; Ueda K; Sano F; Hayashi M; Nishimoto A; Hamano K
J Surg Res; 2016 Feb; 200(2):690-7. PubMed ID: 26428090
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of matrix metalloproteinase-7 and -9 in NSCLC tumor and stromal cells: correlation with a favorable clinical outcome.
Stenvold H; Donnem T; Andersen S; Al-Saad S; Al-Shibli K; Busund LT; Bremnes RM
Lung Cancer; 2012 Feb; 75(2):235-41. PubMed ID: 21764478
[TBL] [Abstract][Full Text] [Related]
15. Correlation between apoptotic index and angiogenesis in non-small cell lung cancer: comparison between CD105 and CD34 as a marker of angiogenesis.
Tanaka F; Otake Y; Yanagihara K; Kawano Y; Miyahara R; Li M; Ishikawa S; Wada H
Lung Cancer; 2003 Mar; 39(3):289-96. PubMed ID: 12609567
[TBL] [Abstract][Full Text] [Related]
16. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
[TBL] [Abstract][Full Text] [Related]
17. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer.
Shou Y; Hirano T; Gong Y; Kato Y; Yoshida K; Ohira T; Ikeda N; Konaka C; Ebihara Y; Zhao F; Kato H
Br J Cancer; 2001 Nov; 85(11):1706-12. PubMed ID: 11742492
[TBL] [Abstract][Full Text] [Related]
18. Expression of angiopoietins and its clinical significance in non-small cell lung cancer.
Tanaka F; Ishikawa S; Yanagihara K; Miyahara R; Kawano Y; Li M; Otake Y; Wada H
Cancer Res; 2002 Dec; 62(23):7124-9. PubMed ID: 12460935
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in resected pathologic (p-) stage IIIA-N2, non-small-cell lung cancer.
Tanaka F; Yanagihara K; Otake Y; Kawano Y; Miyahara R; Takenaka K; Katakura H; Ishikawa S; Ito H; Wada H
Ann Surg Oncol; 2004 Jun; 11(6):612-8. PubMed ID: 15150069
[TBL] [Abstract][Full Text] [Related]
20. Expression of MDA-7/IL-24 and its clinical significance in resected non-small cell lung cancer.
Ishikawa S; Nakagawa T; Miyahara R; Kawano Y; Takenaka K; Yanagihara K; Otake Y; Katakura H; Wada H; Tanaka F
Clin Cancer Res; 2005 Feb; 11(3):1198-202. PubMed ID: 15709189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
